Imagine trying to test a new medicine but not having a safe way to see if it works. This project builds a high-tech 'library' of biological models, using both specialized animals and lab-grown cells. It's like creating a precise biological simulator that helps scientists predict how a human disease will react to a treatment without guessing.
Drug developers face high costs and ethical hurdles when using animal models that don't accurately mimic human diseases. There is a critical need for more precise, validated, and non-animal cellular alternatives.
A suite of pilot services including bespoke mouse model generation, genetic validation of precision models, and the provision of MEFs and mESCs.
If you are a drug discovery firm dealing with high failure rates in clinical trials — this project developed precision disease models and genetic validation services that improve the accuracy of early testing. This reduces the risk of advancing ineffective compounds.
If you are a cell therapy developer dealing with a lack of standardized testing materials — this project developed a provision of MEFs and mESCs. This allows for more consistent scaling of in vitro research.
If you are a preclinical CRO dealing with strict animal welfare regulations — this project developed alternative cellular models to reduce animal usage. This helps you maintain compliance while keeping research speed high.
Based on available project data, specific pricing for the pilot services is not listed, though the project is supported by a EUR 3,999,891 EU contribution.
The project focuses on developing national node capacities and pilot service provision, suggesting a distributed scale across 13 countries.
Based on available project data, the specific licensing terms are not provided, but the project is coordinated by the INFRAFRONTIER ERIC.
The project period runs from 2024-06-01 to 2027-05-31, indicating that services are being refined during this window.
The project includes a strong IT and data management backbone to support the service development strategy and user community needs.
The consortium is heavily weighted toward research and academic institutions, with 14 research entities and 4 universities. However, there is a 10% industry presence consisting of 2 SMEs, indicating that while the project is research-driven, there is a direct link to commercial application and small-scale industrial implementation across 13 countries.
Contact INFRAFRONTIER ERIC in Germany
Contact us to match with the INFRAPLUS pilot service providers.
